Skip to main content

Table 1 Comparison of baseline characteristics of patients with WHO-MDS or WHO-AMLreceiving azacitidine front-line

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

  AML30+ (n = 111) AML20–30 (n = 79) p value AML20–30 (n = 79) RAEB-II (n = 96) p value RAEB-II (n = 96) RAEB-I (n = 53) p value
AZA first-line, % 100 100 1 100 100 1 100 100 1
Age (years), median (range)
 Age ≥75 years, %
77 (23–93)
57.7
77 (44–93)
59.5
1
0.867
77 (44–93)
59.5
72 (37–87)
38.5
0.682
0.034
72 (37–87)
38.5
71 (42–87)
41.5
0.933
0.737
Male, % 55.0 65.6 0.334 65.6 65.6 1 65.6 77.4 0.323
MRFa, % 66.7 78.5 0.327 78.5 100b 0.110 100b 100b 1
Therapy-related, % 4.5 8.9 0.229 8.9 9.4 0.906 9.4 11.3 0.677
PB-blasts (%), median (range)
 ≥0 %, %
4 (0–86)
65.8
2 (0–58)
64.6
0.414
0.916
2 (0–58)
64.6
1 (0–19)
44.8
0.564
0.058
1 (0–19)
44.8
0 (0–4)
37.7
0.317
0.434
ECOG PS, %
 Grades 0–1
 Grade 2
 Grades 3–4
67.6
23.4
9.0
69.6
24.2
6.3
0.865
0.909
0.490
69.6
24.2
6.3
80.2
16.7
3.1
0.386
0.241
0.297
80.2
16.7
3.1
83.0
11.3
5.7
0.827
0.308
0.381
IPSS cytogenetic risk groupc, %
 Good
   Normal karyotype
  Intermediate
 Poor
 Not evaluable
50.5
45.1
14.4
21.6
13.5
46.2
38.5
21.8
20.5
11.5
0.602
0.470
0.219
0.865
0.689
46.2
38.5
21.8
20.5
11.5
48.9
45.7
11.7
30.9
7.3
0.781
0.433
0.081
0.147
0.333
48.9
45.7
11.7
30.9
7.3
45.3
30.2
20.8
24.5
9.4
0.710
0.075
0.110
0.390
0.607
RBC-TD, % 55.9 48.1 0.444 48.1 55.2 0.485 55.2 67.9 0.252
PLT-TD, % 27.9 21.5 0.363 21.5 31.3 0.177 31.3 22.6 0.236
Hb (g/dL), median (range) 9.1 (5.8–14.2) 9.1 (6.3–13.4) 1 9.1 (6.3–13.4) 9.1 (6.7–14.2) 1 9.1 (6.7–14.2) 8.9 (2.5–15) 0.964
PLT (G/L), median (range) 50 (7–1270) 66 (6–1100) 0.137 66 (6–1100) 44 (7–1184) 0.036 44 (7–1184) 51 (8–610) 0.473
WBC (G/L), median (range) 2.5 (0.6–96.0) 2.5 (0.6–41.6) 1 2.5 (0.6–41.6) 2.5 (0.8–96.0) 1 2.5 (0.8–96.0) 2.5 (0.6–13.8) 1
ANC (G/L), median (range) 0.5 (0–37.2) 0.7 (0–28.0) 0.856 0.7 (0–28.0) 0.9 (0–42.0) 0.874 0.9 (0–42.0) 1.1 (0.2–10.9) 0.888
  1. aMRF: MDS-related features, as defined by presence of MDS-related cytogenetics (MRC) and/or antecedent haematological disease (AHD) and/or myelodysplasia
  2. bFor the diagnosis of MDS according to WHO, the presence of myelodysplasia is required in all patients (i.e. 100 %)
  3. cThe IPSS cytogenetic risk score was established for and validated in patients with MDS and is not commonly used to stratify cytogenetic risk in AML patients. However, we used this score for both MDS and AML patients, in order to be able to compare frequencies of karyotypes across these patient groups
  4. WHO World Health Organization, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, RAEB refractory anaemia with excess blasts, AZA azacitidine, PB peripheral blood, ECOG PS Eastern Cooperative Oncology Group performance status, IPSS International Prognostic Scoring System, RBC red blood cell, TD transfusion-dependent, PLT platelet, Hb haemoglobin, WBC white blood cell, ANC absolute neutrophil count